Dermira, Inc. (NASDAQ:DERM) saw unusually-high trading volume on Tuesday . Approximately 1,659,019 shares changed hands during mid-day trading, an increase of 350% from the previous session’s volume of 368,697 shares.The stock last traded at $28.67 and had previously closed at $27.24.
DERM has been the topic of several analyst reports. Zacks Investment Research downgraded shares of Dermira from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 target price on shares of Dermira in a report on Tuesday, July 18th. Mizuho reaffirmed a “buy” rating and issued a $43.00 target price (up previously from $40.00) on shares of Dermira in a report on Thursday, September 7th. Evercore ISI initiated coverage on shares of Dermira in a report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 target price on the stock. Finally, BidaskClub downgraded shares of Dermira from a “buy” rating to a “hold” rating in a report on Monday, July 3rd. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $44.40.
The firm’s 50 day moving average is $25.49 and its 200 day moving average is $28.52. The stock’s market cap is $1.19 billion.
Dermira (NASDAQ:DERM) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.04). Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.00 million. On average, analysts expect that Dermira, Inc. will post ($4.20) EPS for the current year.
In related news, CEO Thomas G. Wiggans sold 9,500 shares of the stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $27.51, for a total value of $261,345.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Fred B. Craves bought 30,000 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was bought at an average price of $23.03 per share, with a total value of $690,900.00. The disclosure for this purchase can be found here. Insiders sold a total of 11,800 shares of company stock valued at $319,751 in the last quarter. 13.30% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc grew its position in Dermira by 16.3% in the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 963 shares in the last quarter. Alliancebernstein L.P. grew its position in Dermira by 4.5% in the 1st quarter. Alliancebernstein L.P. now owns 41,600 shares of the biopharmaceutical company’s stock valued at $1,419,000 after buying an additional 1,800 shares in the last quarter. Nationwide Fund Advisors grew its position in Dermira by 6.5% in the 1st quarter. Nationwide Fund Advisors now owns 30,609 shares of the biopharmaceutical company’s stock valued at $1,044,000 after buying an additional 1,867 shares in the last quarter. SG Americas Securities LLC grew its position in Dermira by 66.8% in the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 2,203 shares in the last quarter. Finally, ProShare Advisors LLC grew its position in Dermira by 12.8% in the 2nd quarter. ProShare Advisors LLC now owns 24,682 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 2,808 shares in the last quarter. Hedge funds and other institutional investors own 97.56% of the company’s stock.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.